Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer

Gastric Cancer

Volumn 10, Issue 2, 2007, Pages 104-111

  Barone, Carlo ^a   Basso, Michele ^a   Schinzari, Giovanni ^a   Pozzo, Carmelo ^a   Trigila, Nunziatina ^a   D'Argento, Ettore ^a   Quirino, Michela ^a   Astone, Antonio ^a   Cassano, Alessandra ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Docetaxel; Gastric cancer; Oxaliplatin; Second line therapy

Indexed keywords

CISPLATIN; COLONY STIMULATING FACTOR; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HISTOLOGY; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERITONEUM METASTASIS; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 34250787547     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-007-0415-x     Document Type: Conference Paper

References (38)

1. DM Parkin 2001 Global cancer statistics in the year 2000 Lancet Oncol 2 533 3
2. JR Kelley JM Duggan 2003 Gastric cancer epidemiology and risk factors J Clin Epidemiol 56 1 9
3. JS Macdonald 2004 Treatment of localized gastric cancer Semin Oncol 314 566 73
4. JK Hu ZX Chen ZG Zhou B Zhang J Tian JP Chen 2002 Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials World J Gastroenterol 8 1023 8
5. B Glimelius K Ekstrom K Hoffman W Graf PO Sjoden U Haglund 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 8
6. A Murad F Santiago A Petroianu PR Rocha MA Rodriguez M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer Cancer 72 37 41
7. S Pyrrhonen T Kuitenen P Nyandoto M Kouri 1995 Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 91
8. JA Wils HO Klein DJ Wagener H Bleiberg H Reis F Korsten 1991 Sequential high dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group J Clin Oncol 9 827 31
9. M Ychou C Astre P Rouanet JM Fabre B Saint-Aubert J Domergue 1996 A phase II study of fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer Eur J Cancer 32A 1933 7
10. P Preusser H Wilke W Achterrath U Fink L Lenaz A Heinicke 1989 Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer J Clin Oncol 7 1310 7
11. G Cocconi M Bella S Zironi R Algeri F Di Costanzo V De Lisi 1994 Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research J Clin Oncol 12 2687 93
12. D Kelsen OT Atiq L Saltz D Niedzwiecki D Ginn D Chapman 1992 FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer J Clin Oncol 10 541 8
13. NK Kim YS Park DS Heo C Suh SY Kim KC Park 1993 A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer Cancer 71 3813 8
14. S Cascinu R Labianca P Alessandroni M Marcellini RR Silva G Pancera 1997 Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione and filgastrim: a report from the Italian Group for the Study of Digestive Tract Cancer J Clin Oncol 15 3313 39
15. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe 1999 Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer J Clin Oncol 80 269 72
16. JS Waters A Norman D Cunningham JH Scarffe A Webb P Harper 1999 Long term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial Br J Cancer 80 269 72
17. U vanhoefer T Wagner M Lutz E Van Cutsem B Nordlinger S Rause 2001 Randomized phase II study of weekly 24 h infusion of high dose 5-FU+/- folinic acid (HD-FU+/-FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC trial 40953 Eur J Cancer 37 Suppl 6 S27 abstract 88
18. C Barone DC Corsi C Pozzo A Cassano T Fontana MR Noviello 1998 Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or cisplatin-based regimen: two parallel randomized phase II studies Cancer 82 1460 7
19. K Fatatsuki A Wakui I Nakao Y Sakata M Kambe Y Shimada 1994 Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group Gan To Kagaku Ryoho 21 1033 8
20. C Pozzo C Barone J Szanto E Padi C Peschel J Bukki 2004 Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study Ann Oncol 15 1773 81
21. Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, et al. Randomized phase 3 trial of irinotecan (CPT-11+ 5FU/folinic acid (FA) vs CDDP + 5FU in first-line advanced gastric cancer patients. J Clin Oncol 2005;23(S16):(abstract no. 4403)
22. AD Roth R Maibach G Martinelli N Fazio MS Aapro O Pagani 2000 Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and European Institute of Oncology (EIO) Ann Oncol 11 301 6
23. M Constenla R Garcia-Arroyo I Lorenzo N Carrete B Campos P Palacios 2002 Docetaxel, 5-fluorouracil and leucovorin as treatment for advanced gastric cancer: results of a phase II study Gastric Cancer 5 142 7
24. JA Ajani M Fodor E Van Cutsem S Tjulandin V Moiseyenko F Cabial 2000 Multinational randomized phase II study of docetaxel (T) and cisplatin (C) with or without 5-flurouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC) Proc Am Soc Clin Oncol 19 247a (abstract 957)
25. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 2005;23(S16):(abstract no. 4002)
26. DY Kim JH Kim SH Lee TY Kim DS Heo YJ Bang 2003 Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer Ann Oncol 14 383 7
27. SE Al-Batran A Atmaca S Hegewisch-Becker D Jaeger S Hahnfeld HJ Rummel 2004 Phase II trial of biweekly infusional fluorouracil, folinic acid and oxaliplatin in patients with advanced gastric cancer J Clin Oncol 22 658 63
28. F De Vita M Orditura E Matano R Bianco C Carlomagno S Infusino 2005 A phase II trial of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first line treatment of advanced gastric cancer patients Br J Cancer 9 1644 9
29. C Louvet T Andre JM Tigaud F Gamelin JY Douillard R Brunet 2002 Phase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients J Clin Oncol 20 4543 8
30. R Tanaka H Ariyama B Qin Y Takii E Baba K Mitsugi 2005 In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines Cancer Chemother Pharmacol 55 595 601 Epub 2005 Feb 25
31. Agelaki S, Kouroussis C, Mavroudis D, Kalbakis K, Souglakos J, Reppa D, et al. A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:abstract 443
32. R Simon PF Thall SS Ellenberg 1994 New designs for selection of treatments to be tested in randomized clinical trials Stat Med 13 417 29
33. C Kunisaki T Imada R Yamada S Hatori H Ono Y Otsuka 2005 Phase II study of docetaxel plus cisplatin as second-line combined therapy in patients with advanced gastric carcinoma Anticancer Res 25 2973 7
34. SH Park WK Kang HR Lee J Park KE Lee SH Lee 2004 Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen Am J Clin Oncol 27 477 80
35. A Polyzos N Tsavaris C Kosmas K Polyzos A Giannopoulos E Felekouras 2006 Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin Anticancer Res 26 3749 53
36. C Tourningand T Andrè E Achille G Lledo M Flesh D Mery-Mignard 2004 FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 15 229 37
37. LM Rothenberg LA Amit RH Bigelow JD Berlin JL Marshall RK Ramanathan 2003 Superiority of oxaliplatin and flurouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial J Clin Oncol 21 2059 69
38. A Grothey D Sargent RM Goldberg HJ Schmoll 2004 Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment J Clin Oncol 22 1209 14